ArticleJournal of the American Chemical Society2026
Site-Specific and Programmable Editing of Serine and Threonine in Unprotected Peptides.
Article in Journal of the American Chemical Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Serine and threonine residues dominate regulatory post-translational modifications in nature, yet remain largely inaccessible to programmable chemical editing. Their weak hydroxyl nucleophilicity and the presence of multiple indistinguishable sites within proteins have prevented the development of general, site-selective strategies for modification in unprotected polypeptides. Here, we report that aminooxy serine or aminooxy threonine can mediate an effective aminooxy ligation (AOL) in aqueous solution through a transient 1,2,4-oxadiazinane intermediate, enabling chemoselective peptide ligation at the N-terminal position. Furthermore, the embedded aminooxy functionality after AOL subsequently undergoes a chemoselective ester ligation (CEL) with keto acids to restore aminooxy into native Ser/Thr and install O-acylation. This two-stage strategy offers site-specific Ser/Thr modification under mild conditions, permitting reductive restoration, neoglycosylation, or O-acylation. Applications range from late-stage modification of therapeutic peptide analogues to the convergent chemical synthesis of histone H2B bearing site-specific O-neoglycosylation and O-acylation. Together, this work establishes a general chemical framework for serine and threonine editing for protein chemical synthesis and engineering.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.